We report a suppurative costochondritis and chest wall abscess in a severe COVID-19 patient treated with tocilizumab.
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:Coronavirus disease 2019 (COVID-19) is a worldwide pandemic, causing a global health threat.
📊
Temel Bulgular & Veri:Up to 15% of the confirmed cases develop severe disease, requiring hospitalization or intensive care unit (ICU) admission.
💡
Sonuç & Katkı:We report a suppurative costochondritis and chest wall abscess in a severe COVID-19 patient treated with tocilizumab.
🔬Tür:Araştırma Makalesi
📍Kapsam:2019 Verileri
⚙️Değişkenler:Alan Parametreleri
Özet
Coronavirus disease 2019 (COVID-19) is a worldwide pandemic, causing a global health threat. Up to 15% of the confirmed cases develop severe disease, requiring hospitalization or intensive care unit (ICU) admission. Tocilizumab, an IL-6 receptor antagonist, is a promising treatment of severe pneumonia with acute respiratory distress syndrome (ARDS) or cytokine release syndrome (CRS) in the course of COVID-19. We report a suppurative costochondritis and chest wall abscess in a severe COVID-19 patient treated with tocilizumab.
🔖
Bu Makaleye Atıf Yap
ERGENÇ, İ., TOPRAK, C. Ş., ODABAŞI, Z. (2021). Staphylococcus aureus costochondritis and chest wall abscess in a COVID-19 patient treated with tocilizumab. Turkish journal of physical medicine and rehabilitation, Cilt: 67 - Sayı: 3, 382–385. https://ajindex.com/articles/408584
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020;395:1054-62
Campbell L, Chen C, Bhagat SS, Parker RA, Östör AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: A systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 2011;50:552-62
Morel J, Constantin A, Baron G, Dernis E, Flipo RM, Rist S, et al. Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE. Rheumatology (Oxford) 2017;56:1746-54
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395:507-13
Nguyen MT, Pødenphant J, Ravn P. Three cases of severely disseminated Staphylococcus aureus infection in patients treated with tocilizumab. BMJ Case Rep 2013;2013:bcr2012007413
Bari SF, Khan A, Lawson T. C reactive protein may not be reliable as a marker of severe bacterial infection in patients receiving tocilizumab. BMJ Case Rep 2013;2013:bcr2013010423
Frigault MJ, Nikiforow S, Mansour MK, Hu ZH, Horowitz MM, Riches ML, et al. Tocilizumab not associated with increased infection risk after CAR T-cell therapy: Implications for COVID-19? Blood 2020;136:137-9
Odabasi Z, Cinel I. Consideration of severe coronavirus disease 2019 as viral Sepsis and potential use of immune checkpoint inhibitors. Crit Care Explor 2020;2:e0141
Derouane F, Lambert M, De Greef J, Malghem J, Lecouvet FE. Primary infectious costochondritis due to Prevotella nigrescens in an immunocompetent patient: Clinical and imaging findings. Skeletal Radiol 2019;48:1305-9
Hanak JA. Tietze syndrome. In: Frontera WR, Silver JK, Rizzo TD editors. Essentials of physical medicine and rehabilitation. Chapter 117. 4th ed. Philadelphia: Content Repository Only; 2020. p. 640-5.